(Q46542215)

23 December 2017

title

Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients (English)

1 reference

23 December 2017

1 reference

1 reference

7

Jean-Paul Soulillou

1 reference

23 December 2017

Klemens Budde

1

1 reference

23 December 2017

Gustav Lehne

2

1 reference

23 December 2017

Michael Winkler

3

1 reference

23 December 2017

Lutz Renders

4

1 reference

23 December 2017

Arno Lison

5

1 reference

23 December 2017

Lutz Fritsche

6

1 reference

23 December 2017

Per Fauchald

8

1 reference

23 December 2017

Hans-Hellmut Neumayer

9

1 reference

23 December 2017

Jaques Dantal

10

1 reference

23 December 2017

RADW 102 Renal Transplant Study Group

11

1 reference

23 December 2017

publication date

1 July 2005

1 reference

23 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

23 December 2017

volume

45

1 reference

23 December 2017

issue

7

1 reference

23 December 2017

page(s)

781-791

1 reference

23 December 2017

Review of the proliferation inhibitor everolimus

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Early clinical experience with a novel rapamycin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Clinical pharmacokinetics of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Pharmacokinetics and metabolism of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

The role of Certican (everolimus, rad) in the many pathways of chronic rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Pharmacokinetics of an Everolimus-Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Therapeutic drug monitoring of cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277196

21 January 2018

Identifiers

DOI

10.1177/0091270005277196

1 reference

23 December 2017

1 reference

23 December 2017